이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Coloplast 관리

관리 기준 확인 4/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Kristian Villumsen

최고 경영자

DKK 21.4m

총 보상

CEO 급여 비율	54.2%
CEO 임기	4yrs
CEO 소유권	0.04%
경영진 평균 재임 기간	4.7yrs
이사회 평균 재임 기간	4.9yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Kristian Villumsen 의 보수는 Coloplast 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2022	DKK 21m	DKK 12m	DKK 5b
Jun 30 2022	n/a	n/a	DKK 5b
Mar 31 2022	n/a	n/a	DKK 5b
Dec 31 2021	n/a	n/a	DKK 5b
Sep 30 2021	DKK 22m	DKK 11m	DKK 5b
Jun 30 2021	n/a	n/a	DKK 5b
Mar 31 2021	n/a	n/a	DKK 4b
Dec 31 2020	n/a	n/a	DKK 4b
Sep 30 2020	DKK 20m	DKK 11m	DKK 4b
Jun 30 2020	n/a	n/a	DKK 4b
Mar 31 2020	n/a	n/a	DKK 4b
Dec 31 2019	n/a	n/a	DKK 4b
Sep 30 2019	DKK 17m	DKK 10m	DKK 4b
Jun 30 2019	n/a	n/a	DKK 4b
Mar 31 2019	n/a	n/a	DKK 4b
Dec 31 2018	n/a	n/a	DKK 4b
Sep 30 2018	DKK 11m	DKK 6m	DKK 4b
Jun 30 2018	n/a	n/a	DKK 4b
Mar 31 2018	n/a	n/a	DKK 4b
Dec 31 2017	n/a	n/a	DKK 4b
Sep 30 2017	DKK 10m	DKK 6m	DKK 4b
Jun 30 2017	n/a	n/a	DKK 3b
Mar 31 2017	n/a	n/a	DKK 3b
Dec 31 2016	n/a	n/a	DKK 3b
Sep 30 2016	DKK 10m	DKK 6m	DKK 3b

보상 대 시장: Kristian 의 총 보상 ($USD 3.06M ) Swiss 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 5.58M ).

보상과 수익: Kristian 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Kristian Villumsen (52 yo)

4yrs

테뉴어

DKK 21,400,000

보상

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...

리더십 팀

이름	위치	테뉴어	보상	소유권
Kristian Villumsen	President & CEO	4yrs	DKK 21.40m	0.043% DKK 10.5m
Anders Lonning-Skovgaard	Executive VP & CFO	8.4yrs	DKK 10.80m	데이터 없음
Allan Rasmussen	Executive Vice President of Global Operations	8.4yrs	DKK 9.60m	0.00015% DKK 36.8k
Nicolai Andersen	Executive Vice President of Innovation	no data	DKK 9.00m	데이터 없음
Paul Marcun	Executive Vice President of Growth	3.9yrs	DKK 11.00m	데이터 없음
Thomas Barfod	Senior Controller & Employees Representative Director	no data	DKK 450.00k	0.000030% DKK 7.4k
Ellen Bjurgert	Vice President of Investor Relations	6.2yrs	데이터 없음	데이터 없음
Dennis Kaysen	Director of Corporate Communications	no data	데이터 없음	데이터 없음
Dorthe Ronnau	Senior Vice President of People & Culture	less than a year	데이터 없음	데이터 없음
Alain Morvan	Senior Vice President of Sales Europe	10.7yrs	데이터 없음	데이터 없음
Rasmus Møller	Senior Vice President of Wound & Skin Care	2.3yrs	데이터 없음	데이터 없음
Manu Varma	Senior Vice President of Chronic Care - North America	4.7yrs	데이터 없음	데이터 없음

4.7yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: 020259063 의 관리팀은 경험 ( 4.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Thomas Barfod	Senior Controller & Employees Representative Director	16.9yrs	DKK 450.00k	0.000030% DKK 7.4k
Carsten Hellmann	Independent Director	5yrs	DKK 690.00k	0.0028% DKK 694.2k
Lars Rasmussen	Chairman of the Board	4yrs	DKK 1.84m	0.098% DKK 24.0m
Niels Louis-Hansen	Deputy Chairman	54.9yrs	DKK 938.00k	21.14% DKK 5.2b
Marianne Wiinholt	Independent Director	2yrs	DKK 880.00k	0.00024% DKK 58.9k
Jette Nygaard-Andersen	Independent Director	7yrs	DKK 600.00k	데이터 없음
Nikolaj Gundersen	Employees Representative Director	4.9yrs	DKK 450.00k	0% DKK 0
Roland Pedersen	Employees Representative Director	4.9yrs	DKK 450.00k	0.00070% DKK 171.7k
Annette Bruls	Independent Director	less than a year	DKK 497.00k	데이터 없음

4.9yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: 020259063 의 이사회는 경험(평균 재직 기간 4.9 년)으로 간주됩니다.

Coloplast 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Coloplast Announces Executive Changes

Less than half of directors are independent

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Less than half of directors are independent

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Recent updates

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Independent Director Birgitte Nielsen has left the company

Upcoming dividend of kr.14.00 per share

Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020)

Third quarter 2021 earnings released: EPS kr.5.89 (vs kr.4.69 in 3Q 2020)

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Less than half of directors are independent

Coloplast A/S Provides Earnings for the Year 2021

Second quarter 2021 earnings released

First quarter 2021 earnings released

Revenue beats expectations

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Revenue misses expectations

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Earnings released

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령